SHARE THIS

• Lysol does not support Dr. Trump’s internal cleaning solution

The company that makes Lysol is urging customers not to consume its cleaning products after President Donald Trump suggested the possibility of injecting disinfectants to protect people from coronavirus.

“And then I see the disinfectant where it knocks it out in one minute. Is there a way we can do something like that by injection inside or almost a cleaning … it would be interesting to check that,” Trump said. “It sounds interesting to me,” he added.

Ingesting or injecting disinfectants is dangerous, according to a medical expert employed by the Trump administration, Food and Drug Administration chief Dr. Stephen Hahn.

• Surging meat prices coming to a store near you

  The closings of the nation’s meat processors are picking up steam, with Tyson’s Waterloo, Iowa plant being the latest. The situation has gotten so dire in the state that the National Guard has been activated to protect supplies. It’s also led to some weird action, with prices for hogs headed sharply lower but prices for pork belly (used to make bacon) doubling in the last four days.

• Mandating worker testing OK with ADA

  Companies can test employees for COVID-19 before permitting them to enter the workplace as long as the tests are accurate and reliable. That’s according to the Equal Employment Opportunity Commission, the U.S. agency that enforces civil rights laws against disability discrimination. Mandatory medical testing is generally prohibited by the ADA, but is allowed if it is “job related and consistent with business necessity.”

• Spending limits and debt control

  Credit card companies are offering customers relief in the form of waiving fees and adjusting payment schedules, but they’re also keeping a tighter rein on spending limits. Discover Financial Services is tightening underwriting strategies for new accounts as well as credit line management amid coronavirus uncertainty. Meanwhile, Synchrony Financial, which handles credit card programs for J.C. Penney, Gap and American Eagle, is using “internal and credit bureau triggers to dynamically reevaluate customers’ creditworthiness.”

• Gilead drug trial raises doubt of a vaccine coming soon

  Gilead may not be the maker of a quick vaccine hoped for. A summary of its remdesivir trial appeared to show that it was a failure against COVID-19. Fighting back, the drugmaker said that the results were mistakenly published and removed from the WHO’s website, and referred to the findings as “inappropriate characterizations.” Gilead’s own clinical trial of the therapeutic is slated to be released at the end of the month.